Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab + Trastuzumab Rezetecan in HER2-low Advanced Breast Cancer
ChiCTR2600130268Phase 2Not yet recruiting
- Sponsor
- Shandong First Medical University
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab, tuvonralimab and trastuzumab rezetecan in breast cancer, sponsored by Shandong First Medical University. Primary endpoint: Objective Response Rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabtrastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600130268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130268.